Effect of testosterone treatment on glucose metabolism in men with type 2 diabetes: A randomized controlled trial

Diabetes Care

Volumn 37, Issue 8, 2014, Pages 2098-2107

  Gianatti, Emily J ^a,b   Dupuis, Philippe ^a,b   Hoermann, Rudolf ^a   Strauss, Boyd J ^c   Wentworth, John M ^d   Zajac, Jeffrey D ^a,b   Grossmann, Mathis ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b AUSTIN HEALTH   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; C PEPTIDE; GLUCOSE; HEMOGLOBIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TESTOSTERONE; TESTOSTERONE UNDECANOATE; ANDROGEN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ABDOMINAL SUBCUTANEOUS FAT; ACUTE HEART INFARCTION; ADULT; AGED; ANDROGEN THERAPY; AORTA STENOSIS; ARTICLE; BLOOD CELL COUNT; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FAT MASS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; INCIDENCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; ISCHEMIC HEART DISEASE; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PROSTATITIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SIDE EFFECT; SLEEP DISORDERED BREATHING; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME; WAIST CIRCUMFERENCE; ABDOMINAL FAT; ANALOGS AND DERIVATIVES; CARBOHYDRATE METABOLISM; COMPLICATION; DIABETES MELLITUS, TYPE 2; INTRAMUSCULAR DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; OBESITY; PHYSIOLOGY;

ABDOMINAL FAT; ADULT; AGED; ANDROGENS; BLOOD GLUCOSE; CARBOHYDRATE METABOLISM; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, INTRAMUSCULAR; INSULIN RESISTANCE; MALE; MIDDLE AGED; OBESITY; TESTOSTERONE;

EID: 84905010469     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-2845     Document Type: Article

References (40)

1. Dhindsa S, Prabhakar S, Sethi M., Bandyopadhyay A, Chaudhuri A, Dandona P. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 5462-5468
2. Kapoor D, Aldred H, Clark S., Channer KS, Jones TH. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 2007; 30: 911-917
3. Grossmann M, Thomas MC, Panagiotopoulos S, et al Low testosterone levels are common and associated with insulin resistance in men with diabetes. J Clin Endocrinol Metab 2008; 93: 1834-1840
4. Ding EL, Song Y, Malik V.S., Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and metaanalysis. JAMA 2006; 295: 1288-1299
5. Dhindsa S, Miller MG, McWhirter C.L., et al. Testosterone concentrations in diabetic and nondiabetic obese men. Diabetes Care 2010; 33: 1186-1192
6. Grossmann M, Gianatti EJ, Zajac JD Testosterone and type 2 diabetes. Curr Opin Endocrinol Diabetes Obes 2010; 17: 247-256
7. Singh R, Artaza JN, Taylor W.E., Gonzalez-Cadavid NF, Bhasin S. Androgensstimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway. Endocrinology 2003; 144: 5081-5088
8. Hamilton EJ, Gianatti E, Strauss B.J., et al. Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy. Clin Endocrinol (Oxf) 2011; 74: 377-383
9. Isidori AM, Giannetta E, Greco E.A., et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf) 2005; 63: 280-293
10. Laaksonen DE, Niskanen L, Punnonen K., et al. The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: a prospective cohort study. J Clin Endocrinol Metab 2005; 90: 712-719
11. Travison TG, Araujo AB, Kupelian V, O'Donnell AB, McKinlay JB. The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men. J Clin Endocrinol Metab 2007; 92: 549-555
12. Wu FC, Tajar A, Pye S.R., et al.; European Male Aging Study Group. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab 2008; 93: 2737-2745
13. Grossmann M. Low testosterone in men with type 2 diabetes: significance and treatment. J Clin Endocrinol Metab 2011; 96: 2341-2353
14. Camacho EM, Huhtaniemi IT, O'Neill TW, et al.; EMAS Group. Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal results from the European Male Ageing Study. Eur J Endocrinol 2013; 168: 445-455
15. Corona G, Rastrelli G, Monami M., et al. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. Eur J Endocrinol 2013; 168: 829-843
16. Spitzer M, Huang G, Basaria S., Travison TG, Bhasin S. Risks and benefits of testosterone therapy in older men. Nat Rev Endocrinol 2013; 9: 414-424
17. Harwood DT, Handelsman DJ Development and validation of a sensitive liquid chromatography-tandem mass spectrometry assay to simultaneously measure androgens and estrogens in serum without derivatization. Clin Chim Acta 2009; 409: 78-84
18. Mari A, Pacini G, Murphy E., Ludvik B, Nolan JJ. A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care 2001; 24: 539-548
19. Chan DC, Watts GF, Ng T.W., et al. Adiponectin and other adipocytokines as predictors of markers of triglyceride-rich lipoprotein metabolism. Clin Chem 2005; 51: 578-585
20. Kapoor D, Goodwin E, Channer K.S., Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006; 154: 899-906
21. R Core Team. R: A language and environment for statistical computing [Internet], 2013. Available from http://wwwR-projectorg/. Accessed 30 March 2014
22. Bates D, Maechler M, Bolker M. lme4: Linear mixed-effects models using S4 classes. R package version 0.999999-2 [Internet], 2013. Available from http://CRANR-projectorg/package=lme4. Accessed 30 March 2014
23. Dandona P, Dhindsa S. Update: Hypogonadotropic hypogonadism in type 2 diabetes and obesity. J Clin Endocrinol Metab 2011; 96: 2643-2651
24. Tajar A, Huhtaniemi IT, O'Neill TW, et al.; EMAS Group. Characteristics of androgen deficiency in late-onset hypogonadism: results from the European Male Aging Study (EMAS). J Clin Endocrinol Metab 2012; 97: 1508-1516
25. Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab 2006; 91: 4335-4343
26. Singh AB, Hsia S, Alaupovic P., et al. The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. J Clin Endocrinol Metab 2002; 87: 136-143
27. Corona G, Monami M, Rastrelli G., et al. Type 2 diabetes mellitus and testosterone: a meta-analysis study. Int J Androl 2011; 34: 528-540
28. Bhasin S, Cunningham GR, Hayes F.J., et al.; Task Force, Endocrine Society. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010; 95: 2536-2559
29. Rana K, Fam BC, Clarke M.V., Pang TP, Zajac JD, MacLean HE. Increased adiposity in DNA binding-dependent androgen receptor knockout male mice associated with decreased voluntary activity and not insulin resistance. Am J Physiol Endocrinol Metab 2011; 301: E767-E778
30. Okauchi Y, Kishida K, Funahashi T., et al. Changes in serum adiponectin concentrations correlate with changes in BMI, waist circumference, and estimated visceral fat area in middleaged general population. Diabetes Care 2009; 32: e122
31. Finkelstein JS, Lee H, Burnett-Bowie SA, et al. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med 2013; 369: 1011-1022
32. Juang PS, Peng S, Allehmazedeh K., Shah A, Coviello AD, Herbst KL Testosterone with Dutasteride, but Not Anastrazole, Improves Insulin Sensitivity in Young Obese Men: A Randomized Controlled Trial. J Sex Med 2014; 11: 563-573
33. Fernández-Balsells M.M., Murad MH, Lane M, et al Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2010; 95: 2560-2575
34. Coviello AD, Kaplan B, Lakshman K.M., Chen T., Singh AB, Bhasin S. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J Clin Endocrinol Metab 2008; 93: 914-919
35. Gopal RA, Bothra N, Acharya S.V., et al. Treatment of hypogonadism with testosterone in patients with type 2 diabetes mellitus. Endocr Pract 2010; 16: 570-576
36. Kalinchenko SY, Tishova YA, Mskhalaya G.J., Gooren LJ, Giltay EJ, Saad F. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol (Oxf) 2010; 73: 602-612
37. Jones TH, Arver S, Behre H.M., et al.; TIMES2 Investigators. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care 2011; 34: 828-837
38. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 1487-1495
39. Matsuda M, DeFronzo RA Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999; 22: 1462-1470
40. Anawalt BD. Is men's health just a single letter? J Clin Endocrinol Metab 2014; 99: 70-72